Belgian consensus on metabolic problems associated with atypical antipsychotics

References

• Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596–601
   PubMed Web of Science ®Google Scholar
• ‘Schizophrenia and Diabetes 2003’. Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. Br J Psychiatry 2004; 184: S112–4
   Google Scholar
• De Hert, M, Van Eyck, D, Peuskens, H, Thys, E, Peuskens, J. Prevalence of impaired glucose tolerance in schizophrenic patients [abstract]. Annual Meeting of the American Psychiatric Society, 2004.
   Google Scholar
• Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2004; 27: S5–10
   Google Scholar
• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, 1999.
   Google Scholar
• Palmer JP, Hirsch IB. What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26: 536–8
   PubMed Web of Science ®Google Scholar
• Tuomi T, Groop L, Zimmet P, Rowley M, Knowles W, Mackay I. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359–62
   PubMed Web of Science ®Google Scholar
• Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708–23
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68–73
   PubMed Web of Science ®Google Scholar
• Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48: 345–7
   PubMed Web of Science ®Google Scholar
• Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 1969; 30: 341–4
   Google Scholar
• Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37: 1849–57
   PubMed Web of Science ®Google Scholar
• Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?. CNS Drugs 2002; 16: 77–89
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30
   PubMed Web of Science ®Google Scholar
• Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003; 5: 669–83
   PubMedGoogle Scholar
• Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002; 325: 243
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–6
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63: 1135–9
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701–23
   PubMed Web of Science ®Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195–212
   PubMed Web of Science ®Google Scholar
• Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patient with schizophrenia. J Clin Psychiatry 2004; 65: 4–18
   PubMed Web of Science ®Google Scholar
• Scheen, A, De Hert, M. Risque de diabete sucre sous antipsychotiques atyptiques. Méd Hyg 2004:1591–6.
   Google Scholar
• Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25: 1107–16
   PubMed Web of Science ®Google Scholar
• Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716–23
   PubMed Web of Science ®Google Scholar
• Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841–52
   PubMed Web of Science ®Google Scholar
• Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735–44
   PubMed Web of Science ®Google Scholar
• Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65: 857–63
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267–72
   PubMed Web of Science ®Google Scholar
• Grundy, SM, Brewer, HB, Jr, Cleeman, JI, Smith, SC, Jr, Lenfant, C, for the Conference Participants. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433–8.
   PubMed Web of Science ®Google Scholar
• Haupt, DW, Newcomer, JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62((Suppl 27)):15–26; discussion 40–1.
   Google Scholar
• Henderson, D. Medical Illness and Schizophrenia. In: J Meyer, Nasrallah, H, editors. WashingtonDC: Am Psy Publishing, 2003.
   Google Scholar
• Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–49
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17–20
   PubMed Web of Science ®Google Scholar
• Nasrallah, H, Korn, M. Metabolic Disorders in Schizophrenia: Relationship to Atypical Antipsychotic Treatment. posted 07/28/2004: Medscape Psychiatry and Mental Health schizophrenia expert column, 2004.
   Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–97
   PubMed Web of Science ®Google Scholar
• Cohn T, Wolever T, Zipursky R, et al. Screening for diabetes and impaired glucose tolerance in patients on antipsychotic medication. J Neuropsychopharmacol 2002; 5(Suppl I): 168
   Google Scholar
• Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatr News 2003; 38: 1a-27
   Google Scholar
• Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087–92
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 26(Suppl 1)33–50
   Google Scholar
• Gough S, Pelever R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatr 2004; 184: S106–11
   Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346: 393–403
   PubMed Web of Science ®Google Scholar
• Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19–26
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003; 25: 1150–71
   PubMed Web of Science ®Google Scholar
• Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–7
   PubMed Web of Science ®Google Scholar